Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 21, 2025 03:00 ET | Source: Belite Bio, Inc

Belite Bio Announces FDA Granting of Breakthrough Therapy Designation for Tinlarebant for the Treatment of Stargardt Disease

Designation is based on the pivotal Phase 3 DRAGON trial interim analysis results demonstrating Tinlarebant’s efficacy and favorable safety profileTrial completion expected by Q4 2025 (including a...
May 13, 2025 21:00 ET | Source: Belite Bio, Inc

Belite Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update

Following a pre-specified interim analysis, an independent Data Safety Monitoring Board (DSMB) recommended the pivotal Phase 3 trial (DRAGON) of Tinlarebant in adolescent Stargardt disease (STGD1)...
May 12, 2025 08:00 ET | Source: Belite Bio, Inc

Belite Bio to Participate in Four Upcoming Investor Conferences

SAN DIEGO, May 12, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative...
May 07, 2025 08:00 ET | Source: Belite Bio, Inc

Belite Bio to Host Webcast on May 14, 2025, to Discuss First Quarter 2025 Financial Results

SAN DIEGO, May 07, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative...
April 29, 2025 08:00 ET | Source: Belite Bio, Inc

Belite Bio Announces Poster Presentations at the Association for Research in Vision and Ophthalmology 2025 Annual Meeting

SAN DIEGO, April 29, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting...
March 17, 2025 06:00 ET | Source: Belite Bio, Inc

Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website

SAN DIEGO, March 17, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a San Diego based clinical stage biopharmaceutical drug development company, today announced that its annual report on...
March 17, 2025 06:00 ET | Source: Belite Bio, Inc

Belite Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Following a pre-specified interim analysis, the Data Safety Monitoring Board (DSMB) recommended the DRAGON trial, a pivotal Phase 3 trial in adolescent Stargardt 1 (STGD1) subjects, proceed without...
March 11, 2025 03:00 ET | Source: Belite Bio, Inc

Belite Bio to Host Webcast on March 17, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results

SAN DIEGO, March 11, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting...
March 04, 2025 08:00 ET | Source: Belite Bio, Inc

Belite Bio to Participate in the Leerink Partners Global Healthcare Conference

SAN DIEGO, March 04, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting...
February 27, 2025 02:00 ET | Source: Belite Bio, Inc

Belite Bio Announces Interim Analysis Results from the Pivotal Global Phase 3 DRAGON trial of Tinlarebant in Adolescent Stargardt Disease Subjects

An independent Data Safety Monitoring Board (DSMB) for the Phase 3 DRAGON trial recommends trial continuation without any modifications, maintaining the sample size at 104 subjects following a planned...